Clinical Trial

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

Study acronym: B-LIFT
Recruiting
View on ClinicalTrials.gov →
Summary
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of individuals. NAFLD is intimately associated with insulin resistance and associated disorders, such as type 2 diabetes, metabolic syndrome and dyslipidemia. Bempedoic acid, an ATP-citrate lyase inhibitor, is recently approved for patients with dyslipidemia as a second line drug. Bempedoic acid reduces liver fat in mice model of NASH. Data regarding the effect of bempedoic acid on human liver fat are scarce. Therefore, the current study is planned to evaluate the effect of bempedoic acid versus standard treatment on liver and pancreatic fat content in patients with NAFLD
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-06; most recent amendment 2025-06-12.
Status change: Not Yet Recruiting → Recruiting 2023-11-01
Trial Details
NCT Number NCT06035874
Lead Sponsor Medanta, The Medicity, India
Collaborators: Diabetes & Endocrinology Foundation
Conditions Type 2 Diabetes, Non Alcholic Fatty Liver Disease
Enrollment 100 participants
Start Date 2023-10-15
Primary Completion 2024-11-01 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-13